Zoryve 0.15 %

Roflumilast, the active ingredient in Zoryve 0.15%, is a phosphodiesterase-4 (PDE4) inhibitor presented as a 0.15% cream for topical use. It is indicated for the treatment of mild to moderate atopic dermatitis in patients aged 6 years and older.

GNH USA supplies Zoryve 0.15% as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Zoryve 0.15% is a topical medication used to manage inflammatory skin conditions.

- Atopic dermatitis: Reduces inflammation, redness, and itching associated with this chronic skin condition. - Plaque psoriasis: Helps alleviate symptoms such as itchy, painful rashes and red patches of skin. - Seborrheic dermatitis: Treats flaky, scaly, and greasy skin on the scalp, face, chest, or other oily body areas.

Zoryve 0.15% may cause various side effects, ranging from common to serious.

Common Side Effects: - Diarrhea - Nausea - Headache - Pain at the application site - Cold-like symptoms (e.g., cough, runny nose, nasal congestion, sore throat) - Trouble sleeping

Serious or Rare Side Effects: - Application site urticaria - Severe allergic reactions, such as rash, itching, swelling, severe dizziness, or trouble breathing.

Zoryve 0.15% should be used with caution and under medical supervision.

- Allergy: Do not use if allergic to roflumilast or any of its ingredients. - Liver impairment: Use with caution in patients with moderate to severe liver impairment. - Pregnancy: Consult a doctor before use during pregnancy. - Children: Not established for use in children under 6 years of age. - Application: Avoid contact with eyes, mouth, or vagina; rinse immediately if contact occurs. - Storage: Store at room temperature, protect from light and moisture, and keep out of reach of children.

Zoryve 0.15% may interact with other medications, requiring careful monitoring.

Major Interactions (Avoid): - None identified.

Moderate Interactions (Monitor Closely): - Other PDE4 inhibitors: May increase the risk of side effects. - Liver enzymes: May affect the metabolism of roflumilast, requiring dose adjustments. - Immunosuppressants: May enhance the immunosuppressive effects.